Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors

• DOI: 10.2147/jir.s328955
• Publication Date: 2021-08-27T14:00:27Z
• Authors: Xin Zhang; Dingyi Yang; Yong Jiang; Luo Huang; Can Wang; Dan Tao; Xianfeng Liu; Yongyang Lei; Yongzhong Wu; Wei Zhou
• Keywords: Tomotherapy; Univariate analysis; Radiation Pneumonitis

We sought to compare the symptomatic radiation pneumonitis (RP) in lung cancer patients treated with helical tomotherapy (HT) versus intensity-modulated radiotherapy (IMRT), and examine predictive value of circulating lymphocyte subsets affecting occurrence RP.Circulating subsets, clinical characteristics, dosimetric parameters pulmonary function were collected from 130 HT (n = 53) or IMRT 77) 2016 through 2020. Symptomatic RP was compared between groups. Binary logistic regression used identify predictors RP.The group had larger planning target volume (319.9 vs 240.8 cc, P 0.041); more ECOG performance status 0-1 (96.1% 79.2%, 0.002); stage III-IV disease (94.8% 37.6%, 0.028); combined systemic therapy (85.7% 69.8%, 0.022). Grade ≥2 comparable groups (16.9% 15.1%, 0.785). For disease, associated lower V10 (31.9% 35.8%, 0.047) incidence grade 5 (0% 9.1%, 0.018). All reduced after radiotherapy. The decrease degree total T cell count CD4+ than (P 0.043, 0.021). In univariate analysis, smoking status, baseline FEV1, higher count, CD8+ B CD4+/CD8+ ratio development RP. CD8+T only risk factor multivariable analysis (OR 1.003; 95% CI: 1.000-1.005; 0.044).IMRT less for cancer. Higher an increased may better preserve IMRT.